Expert Insights

Is Resistance to Hydroxyurea Prognostic for Adverse Outcomes in PV?

Read transcript Close transcript

So, those patients, you know, that stopped responding to the Hydrea have worse disease. Patient that are resistant to Hydrea had worse outcome in terms of survival in general and in terms of increased risk of transformation of the disease. It could be reflecting the biology of the disease at that time point. But we definitely know that Hydrea resistance does impact overall outcome. Again, this is mostly seen as patient had responded to Hydrea and then lost the response or became resistant. In those cases, we are referring to patients needing phlebotomies, not able to control their hematocrit to 45, or not being able to control other counts or symptoms.

And many times the resistance is in the form that patients start developing cytopenias on the lowest dose of Hydrea that basically the physicians cannot continue the Hydrea.

head shot of Dr Komrokji
Rami S Komrokji, MD Clinical Director of the Malignant Hematology Department Moffitt Cancer Center | Tampa, FL
Dr Rami Komrokji is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center and is a professor in medicine and oncologic sciences at the University of South Florida’s College of Medicine. Dr Komrokji has authored or co-authored more than 80 peer-reviewed manuscripts, 20 book chapters, and more than 200 abstracts on hematologic malignancies and is a peer reviewer for such medical journals as Blood, Journal of Clinical Oncology, and Leukemia. Dr Komrokji serves as a member on the MDS Panel of the National Comprehensive Cancer Network® (NCCN®).